Physician profile
Jamie L Stackman
NPI 1134449614
$1,402.61
in general payments reported to CMS, 2019-2025
23 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $178 · 2023: $277 · 2024: $448 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $205.61 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $177.32 | 2021-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $146.65 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $129.01 | 2021-2025 | Gardasil 9, Gardasil, Capvaxive |
| Lilly USA, LLC | $116.61 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.06 | 2021-2024 | Jardiance |
| Astellas Pharma US INC | $82.49 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $73.25 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $71.05 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.54 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.64 | 2022 | |
| Alexion Pharmaceuticals, INC. | $25.84 | 2024 | Ultomiris |
| Sanofi Pasteur INC. | $23.88 | 2023 | |
| Abbott Laboratories | $23.29 | 2023 | Eterna |
| Novartis Pharmaceuticals Corporation | $20.86 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tms Neurohealth Centers INC. | $19.63 | 2025 | Tms Neurohealth Centers INC. |
| Amgen INC. | $18.47 | 2025 | Repatha |
| Insightec,INC | $18.36 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.71 | 2021 | |
| Dynavax Technologies Corporation | $17.08 | 2023 | Heplisav-B |
| Medtronic, INC. | $14.77 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $14.27 | 2022 | |
| Gilead Sciences, INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Stackman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.